Last reviewed · How we verify

Cryptococcal meningitis — Treatment Landscape & Competitive Intelligence

Cryptococcal meningitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cryptococcal meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Diflucan fluconazole Pfizer Inc. Azole Antifungal [EPC] Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase 1990-01-29
Fluconazol Fluconazol Azienda Sanitaria-Universitaria Integrata di Udine Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Cryptococcal meningitis
  2. Pfizer Inc. · 1 drug in Cryptococcal meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cryptococcal meningitis:

Cite this brief

Drug Landscape (2026). Cryptococcal meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cryptococcal-meningitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing